Browsing by Author "Swanepoel, C. R."
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- ItemClinical experience with Repotin, a locally produced recombinant human erythropoietin, in the treatment of anaemia of chronic renal failure in South Africa(Health & Medical Publishing Group, 1996) Swanepoel, C. R.; Moosa, M. R.; Rowland, G. F.; Meyers, A. M.; Botha, B. P.; Smart, A. J.; Goodman, R.; Schall, R.; Keogh, H. J.; Merrifield, E. H.Objective. To evaluate the efficacy and safety of Repotin, a locally produced recombinant human erythropoietin (rHuEPO), in the treatment of the anaemia of chronic renal failure (ACRF). Design. The study consisted of two multicentre non-randomised open stages. Setting. Renal units at several teaching hospitals in South Africa. Participants. Haemodialysis patients with haemoglobin (Hb) levels less than 8.0 g/dl were recruited. The first stage examined 26 patients during 12-week period in which the dose of intravenous rHuEPO was adjusted according to haematological response. In the second stage 27 patients were stabilised with intravenous rHuEPO and then maintained at a Hb level above 8.0 g/dl by subcutaneous administration for up to 1 year. Outcome measures. In both stages, outcome was measured by clinical examination, blood pressure, full haematological parameters and blood chemistry. Results. In stage 1, all patients responded to therapy with a statistically significant increase in Hb from geometric means of 6.28 g/dl to 8.50 g/dl (geometric SDs of 1.17 and 1.20 respectively). The doses used ranged from 25 IU to 125 IU/kg (average 47.1). In the second stage, Hb levels reached a mean of 8.06 g/dl (SD 0.9) and were maintained at target range with an average dose of 55.5 IU/kg three times a week. Apart from changes in serum iron, ferritin (associated with increased haematopoiesis) and potassium, there were no significant alterations in blood chemistry. The incidence of adverse events reported during the 12-month second stage was no greater than that reported for other forms of rHuEPO therapy. Conclusion. Repotin is a safe and effective rHuEPO preparation for the treatment of ACRF.
- ItemSupplemented low-protein diets : are they superior in chronic renal failure?(Health & Medical Publishing Group, 1995) Herselman, M. G.; Albertse, E. C.; Lombard, C. J.; Swanepoel, C. R.; Hough, F. S.Twenty-two patients with chronic renal failure were randomly assigned to a conventional low-protein diet containing 0,6g protein/kg/day or a very-low-protein diet containing 0,6g protein/kg/day supplemented with essential amino acids; they were followed up for 9 months. There were no significant changes in body mass index, arm muscle area, percentage body fat, serum albumin and transferrin levels in any of the groups; neither was there any difference between the groups in respect of these parameters. Renal function, as measured by the reciprocal of serum creatinine over time, stabilised in both groups during intervention, with no significant difference between the groups. There was however no correlation between changes in renal function and changes in blood pressure, or dietary intake of protein, phosphorus, cholesterol, polyunsaturated and saturated fatty acids. There were also no significant changes and no significant differences between the groups in serum levels of parathyroid hormone and alkaline phosphatase, urine cyclic adenosine monophosphate, tubular reabsorption of phosphate, and the theoretical renal threshold for phosphate. The results of this study suggest that the supplemented very-low-protein diet was not superior to the conventional low-protein diet in terms of its effect on protein-energy status, renal function and biochemical parameters of renal osteodystrophy.